ERBB2 and gastric cancer: However, the results of KEYNOTE‐811 showed that immunotherapy, combined with Trastuzumab, and chemotherapy, greatly improved the treatment efficacy of Her2‐positive gastric cancer patients.[7] MSI analysis of gastric cancer in the benefited population revealed only three patients (0.7%) were MSI‐H type gastric cancer, which may suggest that in immunotherapy, pyroptosis‐related markers should be considered in addition to considering traditional biomarkers such as MSI, TMB, and PD‐L1.